Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1:12:858826.
doi: 10.3389/fonc.2022.858826. eCollection 2022.

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer

Qian Chen  1 , Xiaoli Li  1 , Zhen Zhang  1 , Tong Wu  1
Affiliations

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer

Qian Chen et al. Front Oncol. .

Abstract

Objective: To systematically evaluate the efficacy and safety of olaparib in the treatment of recurrent platinum-sensitive ovarian cancer.

Methods: The Cochrane Library, PubMed, Chinese Biomedical Literature Database, CNKI, VIP Database, Wanfang Science and Technology Database were searched for randomized controlled trials (RCTs) of olaparib in the treatment of recurrent platinum-sensitive ovarian cancer from the establishment of each database to January 2022. Two reviewers independently evaluated the quality of the literature, extracted the data, and cross-checked the methodological quality. Meta-analysis was performed using RevMan 5.4 software.

Results: A total of 7 RCTs were included, including 2406 patients, There were 1497 patients in treatment groups and 909 patients in the control group. Meta-analysis results showed that in terms of effectiveness, the overall survival time of patients in the olaparib group [HR=1.24, 95%CI(1.06, 1.45), P=0.006]; in terms of safety, for all grades of adverse events (including nausea, fatigue, vomiting, diarrhea, abdominal pain, and headache), [HR=1.54, 95%CI(1.38, 1.71), P=0.0002], for grade 3 or higher adverse events (including nausea, fatigue, vomiting, diarrhea, abdominal pain, and headache), [HR=2.13, 95%CI(1.61, 2.81), P=0.003], there were significant differences compared with the control group, suggesting that the risk of adverse reactions in the experimental group was higher than that in the control group. Subgroup analysis showed that only abdominal pain, headache and vomiting were not statistically significant, and other adverse reactions were statistically significant.

Conclusion: Based on the existing clinical evidence, olaparib in the treatment of recurrent platinum-sensitive ovarian cancer has a longer overall survival than the control group. It is an ideal regimen, but the incidence of adverse reactions is high.

Keywords: adverse reactions; effectiveness; olaparib; ovarian cancer; safety; total survival time.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA Flow chart of article selection.
Figure 2
Figure 2
Meta-analysis results of OS between control group and olaparib group.
Figure 3
Figure 3
Meta-analysis results of adverse reactions of any grade between control group and olaparib group.
Figure.4
Figure.4
Meta-analysis results of adverse reactions above grade 3 between control group and olaparib group.
Figure 5
Figure 5
Inverted funnel plot of OS.
See this image and copyright information in PMC

References

    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries in 2012. Eur J Cancer (2013) 49:1374–403. doi: 10.1016/j.ejca.2012.12.027 - DOI - PubMed
    1. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2013) 24 Suppl 6:vi24–32. doi: 10.1093/annonc/mdt333 - DOI - PubMed
    1. Poveda AM, Davidson R, Blakeley C, Milner A. Olaparib Maintenance Monotherapy in Platinum-Sensitive, Relapsed Ovarian Cancer Without Germline BRCA Mutations: OPINION Phase IIIb Study Design. Future Oncol (2019) 15:3651–63. doi: 10.2217/fon-2019-0343 - DOI - PubMed
    1. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. (2020) 383:2345–57.
    1. Lazarus G, Audrey J, Iskandar AWB. Efficacy and Safety Profiles of Programmed Cell Death-1/Programmed Cell Death Ligand-1 Inhibitors in the Treatment of Triple-Negative Breast Cancer: A Comprehensive Systematic Review. Oncol Rev (2019) 13:425. doi: 10.4081/oncol.2019.425 - DOI - PMC - PubMed

Publication types

LinkOut - more resources